Proscia, a health IT startup that developed a platform for digital pathology software aimed at clinicians and researchers to make the process of sharing and storing data easier to support cancer diagnoses and treatment, has raised $1 million in a Seed round. The business plans to use the funding to accelerate growth and unlock insights into understanding and treating cancer.
Emerald Development Managers led the round and Robin Hood Ventures, TCP Venture Capital and A-Level Capital participated.
Proscia’s platform lets users integrate multi-gigabyte digital biopsies with storage services from the likes of Dropbox, Amazon, and in-house storage systems. It also provides annotation and collaboration tools.
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
“Precision medicine in the fight against cancer saves lives and long term healthcare costs,” said David West Jr., president and CEO of Proscia in a statement. “Like digital imaging did for radiology, our software will usher in a new era of computer assisted pathology accelerating the fight against life threatening diseases. We are excited and grateful for the support of our investors to help us deliver on our vision.” Check out an interview with West here.
University of Pittsburgh Medical Center and Proscia have a co-development partnership to produce quantitative tools for digital pathology.
Dr. Liron Pantanowitz, Director of Pathology Informatics at UPMC, said in a statement that the kind of image reading capabilities that Proscia has developed will enable clinicians to make more precise diagnoses.
Photo: Flickr user Yale Rosen
Consultants: Help Define What’s Next In Healthcare Benefits
Help shape the future of healthcare benefits by sharing your insights.